7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Atrial Remodeling D064752 1 associated lipids
Vascular Calcification D061205 1 associated lipids
Angina, Stable D060050 2 associated lipids
Bisphosphonate-Associated Osteonecrosis of the Jaw D059266 1 associated lipids
Osteoporotic Fractures D058866 1 associated lipids
Peripheral Arterial Disease D058729 7 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Peri-Implantitis D057873 1 associated lipids
Primary Myelofibrosis D055728 6 associated lipids
Chronic Periodontitis D055113 1 associated lipids
Osteophyte D054850 2 associated lipids
Hyperphosphatemia D054559 1 associated lipids
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative D054438 1 associated lipids
No-Reflow Phenomenon D054318 2 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Hypercalciuria D053565 4 associated lipids
Renal Insufficiency, Chronic D051436 9 associated lipids
Fractures, Bone D050723 4 associated lipids
Arteriolosclerosis D050379 1 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Hashimoto Disease D050031 1 associated lipids
Hyperparathyroidism, Primary D049950 1 associated lipids
Diabetes Complications D048909 4 associated lipids
Hypertension, Pregnancy-Induced D046110 2 associated lipids
Scleroderma, Limited D045745 1 associated lipids
Glucose Metabolism Disorders D044882 3 associated lipids
Malnutrition D044342 6 associated lipids
Irritable Bowel Syndrome D043183 8 associated lipids
Mastocytoma D034801 3 associated lipids
Hearing Loss D034381 3 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Spondylarthropathies D025242 1 associated lipids
Spondylarthritis D025241 1 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Carcinoma, Pancreatic Ductal D021441 6 associated lipids
Multiple Sclerosis, Relapsing-Remitting D020529 7 associated lipids
Multiple Sclerosis, Chronic Progressive D020528 3 associated lipids
Brain Infarction D020520 17 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Lithiasis D020347 2 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Tooth Ankylosis D020254 1 associated lipids
Venous Thrombosis D020246 11 associated lipids
Intracranial Hemorrhage, Traumatic D020198 1 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hot Flashes D019584 5 associated lipids
Bone Marrow Neoplasms D019046 2 associated lipids
Myositis, Inclusion Body D018979 3 associated lipids
Sepsis D018805 11 associated lipids
Arthralgia D018771 8 associated lipids
Systemic Inflammatory Response Syndrome D018746 4 associated lipids
Breast Neoplasms, Male D018567 1 associated lipids
Bone Demineralization, Pathologic D018488 1 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Cholesteatoma, Middle Ear D018424 2 associated lipids
Foot Injuries D018409 1 associated lipids
Alphavirus Infections D018354 1 associated lipids
Hemangioma, Capillary D018324 1 associated lipids
Neoplasms, Squamous Cell D018307 1 associated lipids
Carcinoma, Neuroendocrine D018278 2 associated lipids
Carcinoma, Medullary D018276 2 associated lipids
Carcinoma, Lobular D018275 4 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Adrenocortical Adenoma D018246 1 associated lipids
Fibroma, Ossifying D018214 1 associated lipids
Giant Cell Tumor of Bone D018212 1 associated lipids
Lymphangioleiomyomatosis D018192 1 associated lipids
Bone Cysts, Aneurysmal D017824 2 associated lipids
Diabetic Foot D017719 1 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Microvascular Angina D017566 2 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Myocardial Ischemia D017202 11 associated lipids
beta-Thalassemia D017086 5 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Carotid Stenosis D016893 15 associated lipids
POEMS Syndrome D016878 1 associated lipids
Pasteurellaceae Infections D016871 2 associated lipids
Bacteroidaceae Infections D016866 2 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Diabetes, Gestational D016640 8 associated lipids
Severe Combined Immunodeficiency D016511 1 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Bacteremia D016470 9 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Fractures, Stress D015775 2 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
HIV Infections D015658 20 associated lipids
Histiocytosis, Non-Langerhans-Cell D015616 4 associated lipids
Hyperostosis D015576 1 associated lipids
Arthritis, Psoriatic D015535 3 associated lipids
Leukemia, Lymphocytic, Chronic, B-Cell D015451 25 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
pmid:25240503
pmid:25236333
pmid:27328677
pmid:27318268
pmid:27072583
pmid:27028343
pmid:25016365
pmid:25013993
pmid:26942563
pmid:26936893
pmid:24757095
pmid:24756971
pmid:26648171
pmid:26647458
pmid:24346335
pmid:24337955
pmid:26412665
pmid:26398902
pmid:23104956
pmid:22878484
pmid:26133738
pmid:26131575
pmid:25920618
pmid:25912212
pmid:28363435
pmid:28320782
pmid:25684548
pmid:27925188
pmid:25461399
pmid:25460576
pmid:27729453
pmid:27720655
pmid:28450653
pmid:28429221
Wang Y et al. Puerarin concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production in human osteoblastic MG-63 cells. Phytomedicine pmid:24854571
pmid:12354528
pmid:
Yamamoto N et al. Resveratrol reduces prostaglandin E1-stimulated osteoprotegerin synthesis in osteoblasts: suppression of stress-activated protein kinase/c-Jun N-terminal kinase. Prostaglandins Other Lipid Mediat. pmid:25677506
Hofbauer LC and Heufelder AE Osteoprotegerin: a novel local player in bone metabolism. 1997 Eur. J. Endocrinol. pmid:9368500
Simonet WS et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. 1997 Cell pmid:9108485
Kwon BS et al. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. 1998 FASEB J. pmid:9657524
Yasuda H et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. 1998 Endocrinology pmid:9492069
Hofbauer LC et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. 1998 Biochem. Biophys. Res. Commun. pmid:9784422
Matsuzaki K et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. 1998 Biochem. Biophys. Res. Commun. pmid:9600092
Miyamoto A et al. Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. 1998 Biochem. Biophys. Res. Commun. pmid:9464281
Takai H et al. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. 1998 J. Biol. Chem. pmid:9765225
Lacey DL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. 1998 Cell pmid:9568710
Tomoyasu A et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. 1998 Biochem. Biophys. Res. Commun. pmid:9571159
Bucay N et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. 1998 Genes Dev. pmid:9573043
Yamaguchi K et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. 1998 J. Biol. Chem. pmid:9478964
Yasuda H et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. 1998 Proc. Natl. Acad. Sci. U.S.A. pmid:9520411
Schinke T et al. Molecular determinants of arterial calcification. 1998 Ann. Med. pmid:9920355
Akatsu T et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. 1998 Biochem. Biophys. Res. Commun. pmid:9753612
Hakeda Y et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. 1998 Biochem. Biophys. Res. Commun. pmid:9790989
Horwood NJ et al. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. 1998 Endocrinology pmid:9794488
Vidal NO et al. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. 1998 J. Endocrinol. pmid:9795357
Filvaroff E and Derynck R Bone remodelling: a signalling system for osteoclast regulation. 1998 Curr. Biol. pmid:9768352
Akatsu T et al. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. 1998 Bone pmid:9855457
Morinaga T et al. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. 1998 Eur. J. Biochem. pmid:9688283
Emery JG et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. 1998 J. Biol. Chem. pmid:9603945
Tsukii K et al. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. 1998 Biochem. Biophys. Res. Commun. pmid:9610359
Mizuno A et al. Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis. 1998 Gene pmid:9714833
Mizuno A et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. 1998 Biochem. Biophys. Res. Commun. pmid:9647741
Tsuda E and Higashio K [Osteoclastogenesis inhibitory factor (OCIF)/OPG]. 1998 Nippon Rinsho pmid:9648461
Yamamoto M et al. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. 1998 Endocrinology pmid:9724059
Hofbauer LC and Heufelder AE Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. 1998 Eur. J. Endocrinol. pmid:9724069
Brändström H et al. Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. 1998 Biochem. Biophys. Res. Commun. pmid:9703945
Vidal ON et al. Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. 1998 Biochem. Biophys. Res. Commun. pmid:9703989
Brändström H et al. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. 1998 Biochem. Biophys. Res. Commun. pmid:9642127
Yun TJ et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. 1998 J. Immunol. pmid:9834095
Murakami T et al. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. 1998 Biochem. Biophys. Res. Commun. pmid:9837778
Kong YY et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. 1999 Nature pmid:10580503
Spelsberg TC et al. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. 1999 Mol. Endocrinol. pmid:10379881
Burgess TL et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. 1999 J. Cell Biol. pmid:10225954
Nagai M and Sato N Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. 1999 Biochem. Biophys. Res. Commun. pmid:10208850
Hsu H et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10097072
Shalhoub V et al. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. 1999 J. Cell. Biochem. pmid:10022507
Hofbauer LC et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. 1999 Endocrinology pmid:10499489
Thomas RJ et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. 1999 Endocrinology pmid:10499498
Hofbauer LC Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. 1999 Eur. J. Endocrinol. pmid:10474114
Wickelgren I Mining the genome for drugs. 1999 Science pmid:10475849
Hofbauer LC et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. 1999 Endocrinology pmid:10465311
Morony S et al. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. 1999 J. Bone Miner. Res. pmid:10469275
Sakata M et al. Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells. 1999 J. Bone Miner. Res. pmid:10469276
Lazner F et al. Osteopetrosis and osteoporosis: two sides of the same coin. 1999 Hum. Mol. Genet. pmid:10469835
Itonaga I et al. 1,25-Dihydroxyvitamin D(3) and prostaglandin E(2) act directly on circulating human osteoclast precursors. 1999 Biochem. Biophys. Res. Commun. pmid:10529407
Nakagawa N et al. Basic fibroblast growth factor inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D(3) through suppressing the production of osteoclast differentiation factor. 1999 Biochem. Biophys. Res. Commun. pmid:10548488
Nakagawa N et al. Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells. 1999 Biochem. Biophys. Res. Commun. pmid:10548507
Lee SK and Lorenzo JA Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. 1999 Endocrinology pmid:10433211
Ito H et al. Hedgehog signaling molecules in bone marrow cells at the initial stage of fracture repair. 1999 Biochem. Biophys. Res. Commun. pmid:10462495
Yasuda H et al. A novel molecular mechanism modulating osteoclast differentiation and function. 1999 Bone pmid:10423033
Roodman GD Cell biology of the osteoclast. 1999 Exp. Hematol. pmid:10428500
Zhang XD et al. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. 1999 Cancer Res. pmid:10364001
Kong YY et al. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. 1999 Immunol. Cell Biol. pmid:10234557
Yano K et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. 1999 J. Bone Miner. Res. pmid:10234572
Kanematsu M et al. [Effects of gravity on the gene expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor]. 1999 Biol. Sci. Space pmid:12532992
Sakuma Y et al. Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. 2000 Infect. Immun. pmid:11083800
Riggs BL The mechanisms of estrogen regulation of bone resorption. 2000 J. Clin. Invest. pmid:11086020
Udagawa N et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. 2000 Endocrinology pmid:10965921
Yasuda H [A new paradigm of osteoclast biology: discovery of OCIF and ODF]. 2000 Seikagaku pmid:10967683

Table of Content